Treatment of a Ureteral Stricture Following Failed Management With Ureteral Wall Stent

Filippo, Roger E. De; Kurzrock, Eric A.; Stein, John P.; Skinner, Donald G.

doi:10.1016/s0022-5347(01)62932-x

Cited by 13 publications

(3 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These stents were then used in the ureter for benign and malignant strictures [28] . However, their use in malignant obstruction was hindered by re-occlusion due to endothelial hyperplasia and tumour in-growth through the meshwork of metallic stents [22] . A more recent introduction is a minimally invasive but long-term solution, namely the Memokath 051 TM ureteric stent.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Use of a Segmental Thermoexpandable Metal Alloy Stent in the Management of Malignant Ureteric Obstruction: A Single Centre Experience in the UK

Zaman¹,

Poullis²,

Bach³

et al. 2011

Urol Int

View full text Add to dashboard Cite

Introduction: The Memokath 051™ is a semipermanent inert metal alloy ureteric stent which can bridge strictures and, compared to double J stents, causes less bladder irritation and pain, is more resistant to external compression forces and may be more effective in patients with malignant ureteric obstruction. We present our experience with this novel stent in such cases. Methods: All suitable patients referred to us with malignancy-associated ureteric strictures over a 4-year period had ureteric Memokath 051™ stents inserted. Data on aetiology and position of the strictures as well as length of the Memokath stents used and their efficacy and complications were recorded prospectively. Results: 42 ureteric Memokath 051™ stents were inserted in 37 patients (mean age 64 years). 40.5% of strictures were related to gynaecological cancer, 21% to bowel cancer, 14% were post radiation, 14% occurred in prostate cancer patients and 9.5% were found in other cancers. The mean follow-up was 22 months (range 5–60 months). The main complications were stent migrations in 5, urinary tract infections in 3 and blockage of stent due to progressive transitional cell carcinoma of the ureter in 2 cases. Conclusion: Memokath 051™ ureteric stents are safe, effective and durable in the long-term treatment of malignant strictures.

show abstract

Section: Discussionmentioning

confidence: 99%

“…wallstents, PalmazSchatz and Accuflex stents [21] . However, these are all meshed stents and their usage is hindered by re-occlusion due to endothelial hyperplasia, and tumour in-growth through the meshwork making removal virtually impossible [22,23] .…”

Section: Introductionmentioning

confidence: 99%

Use of a Segmental Thermoexpandable Metal Alloy Stent in the Management of Malignant Ureteric Obstruction: A Single Centre Experience in the UK

Zaman¹,

Poullis²,

Bach³

et al. 2011

Urol Int

View full text Add to dashboard Cite

show abstract

“…L'effet de la résection à ce niveau, permet une réduction tumorale pour pouvoir libérer la partie de l'urètre pelvien emprisonnée dans la prolifération tumorale ou au sein de la fibrose péritumorale. L'issue du bleu de méthylène et l'aperçu du guide sont synonymes de la perméabilité et autorisent l'arrêt de la résection [10,17]. Le taux de succès de la reperméabilisation des sténoses urétérales néoplasiques, secondaires à des cancers prostatiques, est de 79,8 % dans la série de Dubernard et Touiti [15].…”

Section: Discussionunclassified